GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmena PHR.WA · PLN

Consumer Staples · GPW · 🇵🇱 Poland

Compare

2.86

+2.14%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pharmena

Its shares trade on GPW under the ticker PHR.WA. It has been listed since 25 August 2008. In the fiscal year to 31 December 2025, it reported revenue of PLN 1.6m and a net loss of PLN 2.8m. At that date it held total assets of PLN 10.9m and shareholders' equity of PLN 9.6m.

PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Personal Care Products
Listed since
25 Aug 2008
Employees
24
Website
pharmena.eu ↗

Leadership

Pay as last reported

  • Mr. Konrad PalkaChairman of the Management Board, Chief Executive Officer
  • Ms. Marzena WieczorkowskaVice Chairman of the Management Board, Director of Research and Development
  • Ms. Katarzyna KonopackaChief Accounting Officer
  • Dr. Jan AdamusMember of the Supervisory Board
  • Mr. Jacek DauenhauerMember of the Supervisory Board
  • Ms. Agnieszka DzikiMember of the Supervisory Board
  • Mr. Tomasz FilipiakMember of the Supervisory Board
  • Prof. Dr. Jerzy GebickiMember of the Supervisory Board, since 2021
  • Ms. Anna JanickaMember of the Supervisory Board
  • Mr. Zbigniew MolendaMember of the Supervisory Board
  • Mrs. Anna PaczkowskaMember of the Supervisory Board
  • Prof. Anna Sysa-JedrzejowskaMember of the Supervisory Board, since 2011

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pharmena SA has a patented active substance 1-MNA for product development.
  • The company employs 24 full-time employees with a focus on consumer products.
  • Pharmena SA has a wholly owned subsidiary in the United States as of 2011.

Weaknesses

  • The company has a single main shareholder, Pelion SA, indicating potential concentration risk.
  • As of 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake, suggesting significant external ownership influence.
  • The company's product range is limited to specific consumer products without broader diversification.

Opportunities

  • Pharmena SA collaborates with research centers in Europe, the US, and Canada for multidirectional research.
  • The company's products target multiple consumer needs including hair loss, dandruff, acne, and anti-aging.
  • The presence of a U.S. subsidiary could facilitate expansion into international markets.

Threats

  • The company's reliance on a single patented active substance may pose innovation risks.
  • The significant stake held by Polska Grupa Farmaceutyczna SA could lead to governance challenges.
  • The company's IPO date in 2008 suggests potential market volatility or limited recent market activity.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.